The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts
The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study.